In vivo validation of PAX2 as a target for renal cancer therapy

Cancer Letters

Volumn 265, Issue 1, 2008, Pages 148-155

  Hueber, Pierre Alain ^a   Iglesias, Diana ^a   Chu, Lee Lee ^a   Eccles, Michael ^b   Goodyer, Paul ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Apoptosis; Cisplatin; PAX2; Renal cell carcinoma; shRNA

Indexed keywords

CASPASE 3; CISPLATIN; MESSENGER RNA; NEOMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8;

ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CANCER; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; VALIDATION PROCESS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CARCINOMA, RENAL CELL; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PAX2 TRANSCRIPTION FACTOR; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 43449113238     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.016     Document Type: Article

References (30)

1. Muratovska A., Zhou C., He S., Goodyer P., and Eccles M.R. Paired-box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22 (2003) 7989-7997
2. Robson E.J., He S.J., and Eccles M.R. A PANorama of PAX genes in cancer and development. Nat. Rev. Cancer 6 (2006) 52-62
3. Cohen T., Loutochin O., Amin M., Capolicchio J.P., Goodyer P., and Jednak R. PAX2 is reactivated in urinary tract obstruction and partially protects collecting duct cells from programmed cell death. Am. J. Physiol. Renal Physiol. 292 (2007) F1267-F1273
4. Torban E., Eccles M.R., Favor J., and Goodyer P.R. PAX2 suppresses apoptosis in renal collecting duct cells. Am. J. Pathol. 157 (2000) 833-842
5. Daniel L., Lechevallier E., Giorgi R., Sichez H., Zattara-Cannoni H., Figarella-Branger D., and Coulange C. Pax-2 expression in adult renal tumors. Hum. Pathol. 32 (2001) 282-287
6. Mazal P.R., Stichenwirth M., Koller A., Blach S., Haitel A., and Susani M. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod. Pathol. 18 (2005) 535-540
7. Memeo L., Jhang J., Assaad A.M., McKiernan J.M., Murty V.V., Hibshoosh H., Tong G.X., and Mansukhani M.M. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am. J. Clin. Pathol. 127 (2007) 225-229
8. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N. Engl. J. Med. 353 (2005) 2477-2490
9. Hueber P.A., Waters P., Clark P., Eccles M., and Goodyer P. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int. 69 (2006) 1139-1145
10. Dziarmaga A., Hueber P.A., Iglesias D., Hache N., Jeffs A., Gendron N., Mackenzie A., Eccles M., and Goodyer P. Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. Am. J. Physiol. Renal Physiol. 291 (2006) F913-F920
11. Yan Y., Mahotka C., Heikaus S., Shibata T., Wethkamp N., Liebmann J., Suschek C.V., Guo Y., Gabbert H.E., Gerharz C.D., and Ramp U. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br. J. Cancer 91 (2004) 1349-1357
12. Mizutani Y., Nakanishi H., Li Y.N., Matsubara H., Yamamoto K., Sato N., Shiraishi T., Nakamura T., Mikami K., Okihara K., Takaha N., Ukimura O., Kawauchi A., Nonomura N., Bonavida B., and Miki T. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. 30 (2007) 919-925
13. Byun S.S., Yeo W.G., Lee S.E., and Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 69 (2007) 34-37
14. Wu H., Chen Y., Liang J., Shi B., Wu G., Zhang Y., Wang D., Li R., Yi X., Zhang H., Sun L., and Shang Y. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438 (2005) 981-987
15. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22 (2004) 4991-5004
16. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
17. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
18. Zhou M.I., Foy R.L., Chitalia V.C., Zhao J., Panchenko M.V., Wang H., and Cohen H.T. Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc. Natl. Acad. Sci. USA 102 (2005) 11035-11040
19. Cai Q., Dmitrieva N.I., Ferraris J.D., Brooks H.L., van Balkom B.W., and Burg M. Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance. Proc. Natl. Acad. Sci. USA 102 (2005) 503-508
20. Kim D., Wang M., Cai Q., Brooks H., and Dressler G.R. Pax transactivation-domain interacting protein is required for urine concentration and osmotolerance in collecting duct epithelia. J. Am. Soc. Nephrol. 18 (2007) 1458-1465
21. Lechner M.S., Levitan I., and Dressler G.R. PTIP, a novel BRCT domain-containing protein interacts with Pax2 and is associated with active chromatin. Nucleic Acids Res. 28 (2000) 2741-2751
22. Hoffmeister A., Ropolo A., Vasseur S., Mallo G.V., Bodeker H., Ritz-Laser B., Dressler G.R., Vaccaro M.I., Dagorn J.C., Moreno S., and Iovanna J.L. The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. J. Biol. Chem. 277 (2002) 22314-22319
23. Ramp U., Krieg T., Caliskan E., Mahotka C., Ebert T., Willers R., Gabbert H.E., and Gerharz C.D. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. 35 (2004) 1022-1028
24. Gibson W., Green A., Bullard R.S., Eaddy A.C., and Donald C.D. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Lett. 248 (2007) 251-261
25. Buttiglieri S., Deregibus M.C., Bravo S., Cassoni P., Chiarle R., Bussolati B., and Camussi G. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J. Biol. Chem. 279 (2004) 4136-4143
26. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
27. Narlis M., Grote D., Gaitan Y., Boualia S.K., and Bouchard M. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J. Am. Soc. Nephrol. 18 (2007) 1121-1129
28. van de Water F.M., Boerman O.C., Wouterse A.C., Peters J.G., Russel F.G., and Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34 (2006) 1393-1397
29. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., and Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104 (2007) 5715-5721
30. Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., and Chang E.H. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17 (2006) 117-124